{"pub": "investing.com", "url": "https://investing.com/news/technology-news/softbankbacked-vir-biotechnology-raises-143-million-in-us-ipo-1994802", "downloaded_at": "2019-10-11 00:28:46.534187+00:00", "title": "SoftBank-backed Vir Biotechnology raises $143 million in U.S. IPO", "language": "en", "text": "SoftBank-backed Vir Biotechnology raises $143 million in U.S. IPO\n\nTechnology 27 minutes ago (Oct 10, 2019 08:01PM ET)\n\n\u00a9 Reuters. SoftBank-backed Vir Biotechnology raises $143 million in U.S. IPO NEW YORK (Reuters) - Vir Biotechnology (O: ) priced its initial public offering (IPO) at $20 a share on Thursday, at the bottom end of expectations, a fresh blow for SoftBank Group Corp's (T: ) Vision Fund, owner of 21% in the infectious disease researcher. San Francisco-based Vir raised $142.9 million having previously set a price range of $20-$22 per share. The IPO valued Vir at $2.2 billion.\n\nSoftBank-backed Vir Biotechnology raises $143 million in U.S. IPO", "description": "SoftBank-backed Vir Biotechnology raises $143 million in U.S. IPO", "authors": [], "top_image": "https://i-invdn-com.akamaized.net/news/LYNXNPED4E075_L.jpg", "published_at": "2019-10-10"}